Tenaya Therapeutics and Alnylam Pharmaceuticals struck a discovery collaboration under which Tenaya will deliver up to 15 novel genetic targets for Alnylam to develop as RNAi therapeutics. Alnylam provided $10 million upfront and the agreement carries up to $1.13 billion in milestone payments tied to successful development and approvals. Tenaya, which is advancing gene therapies for cardiac disease, will support the target generation and discovery work while Alnylam brings RNAi development and commercialization capabilities. The collaboration marks Alnylam’s expansion into first‑major cardiovascular partnering beyond its established rare‑disease focus. RNA interference (RNAi) uses small interfering RNAs to silence disease‑causing genes; partnering with target‑rich genomics platforms accelerates identification of candidates suited to knockdown modalities and to the liver‑directed delivery expertise Alnylam has scaled.